AHL Partners LLP grew its stake in Thermo Fisher Scientific Inc (NYSE:TMO) by 242.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 24,130 shares of the medical research company’s stock after purchasing an additional 17,076 shares during the quarter. AHL Partners LLP’s holdings in Thermo Fisher Scientific were worth $4,210,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of TMO. Proficio Capital Partners LLC raised its stake in shares of Thermo Fisher Scientific by 71.5% in the 1st quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after purchasing an additional 253 shares in the last quarter. Chicago Partners Investment Group LLC acquired a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $108,000. Cribstone Capital Management LLC raised its stake in shares of Thermo Fisher Scientific by 8.7% in the 2nd quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock valued at $109,000 after purchasing an additional 50 shares in the last quarter. Sharkey Howes & Javer raised its stake in Thermo Fisher Scientific by 1.0% during the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock worth $113,000 after acquiring an additional 7 shares during the period. Finally, Shine Investment Advisory Services Inc. acquired a new stake in Thermo Fisher Scientific during the second quarter worth about $113,000. Institutional investors and hedge funds own 83.61% of the company’s stock.

Several equities research analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Monday. Deutsche Bank AG set a $226.00 price objective on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Thursday, October 26th. Leerink Swann reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Monday. Jefferies Group LLC reiterated a “hold” rating and set a $195.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, September 28th. Finally, BidaskClub lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $205.71.

WARNING: This news story was published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.watchlistnews.com/thermo-fisher-scientific-inc-tmo-stake-raised-by-ahl-partners-llp/1675015.html.

In related news, Director Jim P. Manzi sold 1,000 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $175.20, for a total transaction of $175,200.00. Following the completion of the transaction, the director now directly owns 38,757 shares of the company’s stock, valued at approximately $6,790,226.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jim P. Manzi sold 11,318 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 18th. The shares were sold at an average price of $172.94, for a total transaction of $1,957,334.92. Following the transaction, the director now directly owns 38,757 shares of the company’s stock, valued at $6,702,635.58. The disclosure for this sale can be found here. Insiders have sold a total of 22,738 shares of company stock valued at $4,021,512 over the last three months. 0.49% of the stock is currently owned by insiders.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The firm had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $5.03 billion. During the same period last year, the firm posted $2.03 EPS. The firm’s quarterly revenue was up 13.9% on a year-over-year basis.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.